[caption id="attachment_73447" align="alignleft" width="142"] Dr. Edward Liu[/caption] MedicalResearch.com Interview with: Edward Liu, MD Geisinger College of Health Sciences Scranton, PA 18509 Medicalresearch.com: What is the background for this study? Response: Prescription drugs have high levels of uniformity that plant-based products cannot achieve.  Given the liberalization of state-laws regarding medical marijuana¹ over the past three-decades and increasing evidence of evidence of cannabis for conditions like chronic pain,² we were interested in the use of the prescription formulation of delta(Δ)9-tetrahydrocannabinol (THC).  A prior pharmacoepidemiology report found that prescription THC (dronabinol) to Medicaid patients decreased from 2016 to 2020. There were also pronounced state-level disparities in prescribing with a 130-fold difference when correcting for population between the highest and lowest states. There was no research on this topic among Medicare patients. To address this gap, we obtained prescription numbers nationally and at a state level from 2014 to 2019 for Medicare Part D patients.